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Natural killer (NK) cells are innate immune lymphocytes that are critical for normal host defense against infections and mediate
antitumor immune responses. MicroRNAs (miRNAs) are a family of small, noncoding RNAs that posttranscriptionally regulate
the majority of cellular processes and pathways. Our understanding of how miRNAs regulate NK cells biology is limited, but
recent studies have provided novel insight into their expression by NK cells, and how they contribute to the regulation of NK
cell development, maturation, survival, and eﬀector function. Here, we review the expression of miRNAs by NK cells, their
contribution to cell intrinsic and extrinsic control of NK cell development and eﬀector response, and their dysregulation in NK
cell malignancies.
1. Introduction
NK cells are innate immune lymphocytes that are important
for host defense against pathogens and exhibit antitumor
responses [1–4]. They develop from progenitors in the bone
marrow through a series of intermediates, which depend on
growth factors and cytokines to support their development
and peripheral homeostasis, especially IL-15 [1, 5, 6]. In
humans, NK cells are identiﬁed as CD56+CD3− lymphocytes
without rearranged T cell receptors and may be divided into
developmentally and functionally distinct subsets based on
the expression of CD56 and CD16 (FcγRIIIa), CD56bright and
CD56dim [4]. In mice, NK cells are identiﬁed by the NK1.1
or NKp46 activating NK cell receptors in CD3−CD19−
lymphocytes [6]. NK cells undergo ﬁnal steps of maturation
in peripheral lymphoid organs, which can be marked by
coexpression of CD27 and CD11b [7]. NK cells mediate
several eﬀector functions, including production of cytokines
and chemokines, as well as cytotoxicity against appropriately
recognized virus-infected and tumor target cells [8]. NK
cells recognize abnormal cells with loss of self markers
detected by inhibitory receptors that recognize classical and
nonclassical MHC class I molecules, which are subject to an
education process that includes licensing [9, 10]. NK cells
are stimulated via activating NK cell receptors that bind to
ligands expressed on infected, malignant, or stressed cells.
The balance of activating and inhibitory receptor signaling
determine whether NK cells are triggered by a potential
target cell [11, 12]. In addition, NK cells express a number
of cytokine receptors and are activated by proinﬂammatory
cytokines, which prime them for optimal eﬀector function,
and overcome some inhibitory based signals [4, 13–16].
Thus, NK cells have a unique biological program that is
highly regulated and distinct from adaptive T and B lympho-
cytes. The molecular events and program that deﬁne NK cells
are incompletely understood and remains a critical area of
NK cell investigation.
The signiﬁcance of NK cells to human health is high-
lighted by multiple patients with selective NK cell deﬁciency,
who present with recurrent, often fatal herpesvirus infections
early in life [17, 18]. Such studies are complemented by
a pediatric patient with T and B cell severe combined
immunodeﬁciency (SCID) that mounted a potent NK cell
response to human cytomegalovirus (CMV) [19], indicating
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that NK cells may provide host protection against viral
pathogens in the absence of adaptive immunity. Such
patients are rare, but highlight the importance of NK cells
to human health. Further, numerous studies in mice have
corroborated the importance of NK cells to host defense
against many infectious pathogens, and have provided the
mechanistic ﬁndings to better understand the contribution
of NK cells to anti-microbial host defense [8, 20, 21].
NK cells also respond to malignant tumor cells and rep-
resent an important immunotherapeutic eﬀector for cancer,
particularly hematologic malignancies [22–26]. In a large
epidemiologic study, low NK cell function was associated
with an increased risk of developing cancer [27]. The
widespread use of monoclonal antibody therapy for cancers,
especially lymphoma, depends on autologous antibody-
dependent cellular cytotoxicity mediated in part by NK cells
[28]. Clear evidence of NK cell activity against cancer in
patients arises from haploidentical stem cell transplantation
[29] and adoptive NK cell therapy studies [30] in acute
myeloid leukemia (AML). These studies directly link an
allogeneic NK cell anti-AML response, controlled in part by
NK receptors, to leukemia clearance and long-term survival
for these patients. These reports underscore the signiﬁcance
and promise of NK cells as eﬀectors against this disease,
and potentially other malignancies. Moreover, these ﬁndings
indicate that a better understanding of basic NK cell biology
will inform future strategies to use NK cells as anticancer and
infectious disease eﬀector cells [23].
Currently, our understanding of the basic molecular
mechanisms regulating NK cell development, maturation,
survival, and function is incomplete. A number of tran-
scription factors have been identiﬁed that contribute to
key aspects of the NK cell molecular program [32, 33]. In
addition, studies have suggested that specialized NK cell
eﬀector functions (i.e., IFN-γ, perforin, and granzymes)
are controlled, at least in part, at the posttranscriptional
level [14, 34]. Recently, the posttranscriptional mechanisms
operative in NK cell have begun to be unraveled, and this
paper focuses on new studies that implicate miRNAs as
important regulators of NK cell biology. As our knowledge
of the molecular programs, including miRNAs, that regulate
NK cells increases, this will lead to identiﬁcation of novel
molecules and pathways that may be manipulated to enhance
or attenuate NK cell function.
2. MicroRNAs
MicroRNAs (miRNAs) are a family of hundreds of small,
noncoding RNAs that regulate numerous cellular functions
primarily by targeting sites in the 3′UTR of mRNAs thereby
suppressing translation or causing mRNA degradation [41].
An alternative mode of action whereby a miRNA increases
mRNA translation in stressed cells via binding to the 5′UTR
was reported [42], but it remains unclear whether this
applies to other miRNAs. MiRNA genes are present in the
genome (with >1000 miRNA sequences predicted in humans
and mice), transcribed as long primary (pri-miRNA) tran-
scripts that are subsequently “cropped” by the Drosha/Dgcr8
complex into precursor miRNA (pre-miRNA) that have a
characteristic stem loop structure [43]. The pre-miRNA is
exported to the cytoplasm where it is further processed by
the Dicer complex (including Dicer1), yielding mature 19–
26 nucleotide miRNAs. The mature miRNA is loaded into
the RNA-induced silencing complex (RISC) that includes
Argonaute proteins and thereby directs down-regulation of
protein levels [44–46]. Thus, the mature miRNA is the
“business end” of the miRNA gene and is highly relevant to
their regulatory function (Figure 1).
MiRNA biogenesis is regulated at multiple levels, and
private components have been identiﬁed that may control
individual miRNA expression levels. Further, many miRNAs
exist in families, with closely related members that share key
binding speciﬁcity sequences, including the “seed” sequence
that is one major determinant of target speciﬁcity. These
families of miRNAs are thought to cooperate in their regula-
tion of target genes, and thus miRNA loss-of-function exper-
iments should account for all expressed family members of
a given family. MiRNAs can be computationally predicted
to bind to hundreds of target mRNAs, but these predictions
are prone to false positive, and negatives, and thus it is
critical to biochemically and biologically validate predicted
miRNA: messenger RNAs target interactions. In addition,
multiple disparate mature miRNAs likely regulate the same
mRNA via distinct and/or overlapping 3′UTR binding sites.
MiRNAs classically limit protein translation and thereby
inﬂuence a broad spectrum of cellular processes, including
cell division, survival, traﬃcking, intracellular signaling,
adhesion, and metabolism. Therefore, it is not surprising that
miRNA dysregulation has also been consistently linked to
malignant transformation [47, 48]. The precise contribution
of these two predominant miRNA repression mechanisms,
mRNA degradation versus translational blockade, remains
controversial, and it is likely both operate in mammalian
cells.
In immunity, the role of miRNA-mediated regulation is
well characterized in adaptive T and B lymphocytes, where
they inﬂuence development as well as peripheral functions,
clearly supported by mouse models of miRNA gain and
loss of function [49]. While miRNA regulation of NK cell
function remains a key question in the NK cell ﬁeld [3],
this paper synthesizes recent studies that have provided the
ﬁrst insights into the expressed mouse and human NK cell
miRNA transcriptomes and mechanisms whereby miRNAs
regulate NK cell development, homeostasis, and functional
responses.
3. MicroRNA Expression by NK Cells
Several studies have proﬁled across diﬀering cell types
to identify miRNA “signatures” within the hematopoietic
system, for example [50–52]. Many of these studies utilized
Sanger sequencing of small RNA clones or miRNA microar-
rays, which oﬀer comparatively less dynamic range of detec-
tion and/or limited miRNA interrogation, relative to unbi-
ased next-generation small RNA sequencing approaches. To
date, three studies utilizing next-generation sequencing have
been reported in mouse and human NK cells. The top
20 expressed miRNAs by human or mouse NK cells from


















Figure 1: Schematic summary of miRNA biogenesis and mechanism of action to inhibit protein translation.
each study are listed in Table 1. We reported the miRNA
transcriptome of resting and IL-15 activated murine splenic
NK cells [37]. The miRNA proﬁles of resting and 24-hour
IL-15 activated splenic NK cells were largely similar, con-
ﬁrmed with several orthogonal techniques including Agilent
microarrays and RT-qPCR, and the top altered miRNAs
are listed in Table 2. Two additional studies sequenced the
small RNA compartments of resting and IFN-alpha [35]
or IL-2/-15/-21 [36] activated human peripheral blood
CD56+CD3− NK cells. While the majority of signiﬁcantly
changed miRNAs in IFN-alpha treated NK cells were down
regulated, most miRNAs in IL-2/-15/-21 treated cells were
upregulated. These diﬀerences may reﬂect miRNA changes
that are speciﬁc to the mode of NK cell stimulation or the
time frame of measurement. It remains to be resolved why
miRNAs ranked in the top 10 in resting NK cells from each
study are diﬀerentially regulated despite two similar end-
processes cytokine activation. One possible explanation is
that proﬁling from these studies was limited to a single
human donor and therefore reﬂects the biological variation
inherent to human NK cells. Other explanations may be
technical-diﬀering RNA preparation (which inﬂuences small
RNA loss during isolation), library construction, sequencing
approaches, or bioinformatics issues including normaliza-
tion.
Thus, there remains a great need in ﬁeld to report
high-quality unbiased miRNA expression analysis including
multiple biological replicates in human and mouse NK
cells and their developmental and functional subsets, and
complete deposition of proﬁling data in raw formats in
public databases to promote cross-study comparisons. For
example, do CD56bright and CD56dim human NK cells express
diﬀerent miRNAs? Do CD56dim NK cell subsets with func-
tional diﬀerences based on CD94, NKG2A, or CD57 diﬀer
in their miRNA proﬁles? Do mouse NK cells at diﬀerent
stages of maturation and function based on CD27 and CDllb,
thymic versus splenic NK cells, and diﬀering stages of NK
cell developmental intermediates express similar miRNAs?
Further, priming and activation results in profound changes
in NK cell functionality, and stimulation through diﬀerent
receptors (cytokine receptors, activating NK cell receptors,
adhesion molecules) may diﬀerentially alter miRNA expres-
sion. Do NK cell miRNA proﬁles diﬀer during viral infection,
licensed versus unlicensed state, or naı¨ve versus memory/
memory-like NK cells? Additional work will also be needed
to fully understand how changes in miRNA levels are
mechanistically induced, their time courses of alteration, and
how physiologic changes inﬂuence their targeted mRNA.
4. Impact of Global MicroRNA
Alteration in NK Cells
A large repertoire of mature miRNAs is expressed by NK
cells [37], which depend on processing enzymes including
Drosha/DGCR8 and Dicer1 (Figure 1). Thus, knockout of
critical miRNA processing genes, resulting in the “global
loss” of mature miRNA expression, has been used to reveal
whether miRNA regulation per se is important for a cell
lineage’s development and/or function. The ﬁrst functional
studies of miRNA in lymphocytes utilized Dicer1 knockout
mice to eliminate all Dicer1-dependent miRNAs and were
focused on T cells [53, 54]. These studies found that
global reductions of mature miRNA led to increased IFN-γ
production and activation, with a severe loss of cell numbers
and proliferation. Similarly, more recent studies focused on
NK cells have reported comparable results (Table 3), with a
few notable diﬀerences.
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Table 1: Top expressed miRNAs in three studies, detected and enumerated by small RNA Illumina sequencing of resting human CD56+CD3−
human [35, 36] or NK1.1+CD3− murine [37] NK cells. The Wang et al. data is limited to the 12 miRNAs reported in the published paper,
since the data was not provided in supplemental ﬁles nor deposited in public databases.
Rank Wang, 2012 (human) [35] Liu, 2012 (human) [36] Fehniger, 2010 (mouse) [37]
1 hsa-miR-21 hsa-let-7f mmu-miR-21
2 hsa-let-7f hsa -let-7g mmu-miR-16
3 hsa-let-7a hsa-let-7a mmu-miR-142-5p
4 hsa-miR-140-3p hsa-miR-423-5p mmu-miR-142-3p
5 hsa-miR-146b-5p hsa-miR-140-3p mmu-miR-24
6 hsa-let-7g hsa-miR-320a mmu-miR-29a
7 hsa-miR-142-3p hsa-let-7b mmu-miR-26a
8 hsa-miR-101 hsa-let-7i mmu-miR-150
9 hsa-miR-378 hsa-miR-29a mmu-let-7f
10 hsa-let-7b hsa-miR-103 mmu-let-7g
11 hsa-miR-103 hsa-miR-101 mmu-miR-22









Table 2: Selected up- or down-regulated miRNAs during cytokine activation of NK cells. miRNAs were selected based on the following
criteria: top three fold change within the top 12 expressed miRNAs [35], signiﬁcant miRNAs consistently changed by the listed stimulation
[36], and top three fold change [37].
Wang, 2012 (human) [35] Liu, 2012 (human) [36] Fehniger, 2010 (mouse) [37]
Stimulation IFN-α IL-2, IL-15, or IL-21 IL-15









Bezman et al. used an inducible (estrogen receptor, ER)
Cre model combined with LoxP-ﬂanked Dicer1 and DGCR8
alleles to eliminate miRNAs in all cells in the mouse following
tamoxifen treatment [38]. Narrowing their focus to the
impact of this miRNA loss on NK cells, this study showed
increased NK cell apoptosis in the periphery, combined with
a selective loss of more mature CD11b+CD27 NK cells, as
well as reduction in surface expression of the activating
NK cell receptor NKG2D. These ﬁndings were coupled with
reduced IFN-γ production and degranulation (CD107a sur-
face expression) following stimulation with anti-NK1.1, anti-
Ly49H, and anti-NKp46, but not stimulation with cytokines
such as IL-12 and IL-18. The authors concluded that miRNAs
are essential regulators of NK cell development and ITAM-
based stimulation of NK cells. In addition, miRNA-deﬁcient
Ly49H+ NK cells robustly proliferated in response to MCMV
infection, but did not survive, and thus were not able to
mount an eﬀective NK cell MCMV response. However, these
results may have complex interpretations inﬂuenced by NK
cell extrinsic factors, since the utilized model resulted in
global mature miRNA loss in all cells in the organism.
Our laboratory utilized a more speciﬁc Cre model to
investigate the results of Dicer1-depenedent miRNA loss
[39]. We used hCD2-Cre transgenic mice [55], which express
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Table 3: Summary of global miRNA-deﬁcient or over-expression (Eri1−/−) NK cells. ∗In particular, at latest stages of NK cell maturation.
∗∗In response to activating (ITAM) receptor-mediated stimulation.
Bezman et al. [38] Sullivan et al. [39] Thomas et al. [40]
Cre Model ER-Cre hCD2-Cre Global Knockout
Gene Dicerﬂ/ﬂ/DGCR8ﬂ/ﬂ Dicerﬂ/ﬂ Eri1−/−
Eﬀect on miRNAs ↓ ↓ ↑
Proliferation ↓ ↓ ↓
# NK Cells ↓∗ ↓∗ ↓∗
Survival ↓ ↓ ↔






↓NKG2D None Observed Multiple, especially↓Ly49H/D
MCMV Response
↔ IFN-γ production
↓Ly49H+ NK Cells ↑IFN-γ Production
↔ IFN-γ production
↓Ly49H+ NK Cells
In vitro Cytotoxicity Not reported Not reported ↔
Cre from the early stages of NK cell development in the
bone marrow, shown by crossing with a Rosa26-LoxP-STOP-
LoxP-YFP knock-in reporter mouse [39]. Thus, in these
experiments Dicer1 was removed from NK cells (marked
by concurrent YFP expression) during the earliest stages
of development, in contrast to eliminating Dicer1 from
mature peripheral NK cells at various stages of development
or maturation. Additionally, the hCD2-Cre transgene was
expressed in a lymphocyte restricted manner, and, while not
completely NK cell speciﬁc [56, 57], removes many potential
confounders by providing Dicer1-competent hematopoietic
and non-hematopoietic cells, except for lymphocytes. This
model conﬁrmed the reduced numbers and percentages of
NK cells, and reduced in vitro survival and proliferation,
indicating that NK cell development and homeostasis are
critically regulated by miRNAs. However, in the hCD2-
Cre mice, NK cells produced increased IFN-γ and had
enhanced degranulation (CD107a surface expression) in
response to multiple activating stimuli, which contrasted
with the hypofunctionality reported in the induced whole-
mouse miRNA loss model [38]. Further, these ﬁndings
in hCD2-Cre mice were corroborated by increased IFN-γ
production by NK cells in vivo during MCMV infection,
which was also evident in mice heterozygous for the LoxP-
ﬂanked Dicer1 allele. Recently, NK cell-speciﬁc Cre models
have been reported driven by NKp46/Ncr1 promoters in
a BAC transgenic [56], or NKp46/Ncr1 by knock-in [57].
Thus, the tools are now available to deﬁnitively evaluate both
global and speciﬁc miRNA loss and gain of function in NK
cells, without confounders from other cell types.
Another study by Thomas et al. [40] focused on Eri1,
a highly conserved exoribonuclease that is involved in 5.8S
rRNA 3′ end processing and a negative regulator of global
miRNA abundance. The authors found that Eri1-deﬁcient
NK and T cells displayed an increase in global miRNA
abundance. NK cells seemed particularly susceptible to the
eﬀects of Eri1 loss and displayed decreased percentage and
numbers, especially at the latest stages of development. The
Eri1-deﬁcient NK cells displayed an altered cell receptor
repertoire, including altered Ly49H expression. In addition,
while Eri1−/− NK cells did not show a defect in IFN-γ pro-
duction in response to IL-12 and IL-18, they produced less
IFN-γ in response to ITAM-dependent activating receptors.
Eri1-deﬁcient NK cells also showed a decreased proliferation
in response to MCMV infection, with increased viral titers,
demonstrating the importance of Eri1 (probably due to
miRNA alterations) in the context of viral infection. While
Eri1-deﬁcient NK cells have changes in global miRNA
expression and a clear development, maturation and func-
tional phenotype, one caveat to these ﬁndings acknowledged
by the authors is that other RNA species are aﬀected by
Eri1, thereby providing alternative explanations for the NK
cell phenotype. Therefore, this study clearly implicates Eri1-
mediated RNA processing in NK cell development and
functional responses, probably reﬂective of global miRNA
changes in NK cells.
Collectively, the preponderance of evidence suggests that
miRNAs promote cellular survival, maturation, and prolif-
eration, while suppressing the production of key immune
cytokines such as IFN-γ. However, the study by Thomas et
al. suggests that miRNA-inﬂuenced genes are perturbed with
either global overexpression or repression: increased miRNA
expression can also aﬀect NK cell homeostasis, supporting a
role of miRNAs as “ﬁne tuners” of cellular homeostasis. The
eﬀects of total miRNA elimination or increase on speciﬁc
functions of NK cells, however, are diﬃcult to extricate
from eﬀects on survival, and thus studying the cell intrinsic
eﬀects of individual miRNAs in NK cells will be a productive
approach to identifying speciﬁc miRNA eﬀects and their
downstream mRNA targets and mechanisms.
5. MicroRNA Regulation of
NK Cell Development
NK cells originate from hematopoietic stem cells in the bone
marrow, and as they mature, they require the expression
of a number of signaling proteins and transcription factors
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essential for the NK lineage [1, 5, 6, 58]. As noted above,
global alteration of miRNAs in NK cells results in perturbed
NK cell development; however, little is known about the role
of speciﬁc miRNA regulation of NK cell development. To
date, two miRNAs and their targeted molecules have been
implicated in this process: miR-150 targeting c-Myb, and
miR-181a/b targeting NEMO-like kinase (NLK).
MiR-150 was ﬁrst identiﬁed as a highly expressed miRNA
in the T and B lymphocyte lineage, with expression corre-
lating to the degree of cell maturity [59]. In mice, miR-150
expression acts as a ﬁne tuner of B cell production through
the targeting of c-Myb, a transcription factor with multiple
roles in hematopoiesis [60, 61]. The role of this miRNA in
regulating T cells is less clear, since miR-150 overexpression
only modestly reduces mature T cell numbers, in part
through c-Myb. Notch3, a receptor important to thymocyte
diﬀerentiation is another possible target of miR-150 [62].
The Lanier group reported that miR-150−/− mice have a
deﬁciency of mature NK cells resulting from defects in
maturation and proliferation [63]. Furthermore, mature
NK cells from miR-150−/− mice produce less IFN-γ upon
cytokine stimulation. The authors suggest that, as in B and
T lymphocytes, miR-150 likely regulates NK development
through targeting c-Myb, since c-Myb+/− heterozygous mice
phenocopy the miR-150−/− NK cell phenotype. This is the
ﬁrst example of miRNA regulating a key transcription factor
thereby regulating NK cell development and maturation.
Like miR-150, two miR-181 family members, miR-181a
and miR-181b, are also expressed in lymphocytes in a stage-
speciﬁc manner. Ectopic expression in murine models results
in increased B cell [64] and T cell numbers [65]. Using
an in vitro NK cell diﬀerentiation system, Cichocki et al.
demonstrated that miR-181 expression increases in parallel
with the maturation stages of human NK cells. Further, over-
expression of miR-181a or miR-181b in CD34+ progenitor
cells that are cultured in vitro in NK cell diﬀerentiation
conditions results in an increased output of CD56+CD3
NK cells [66]. In this study, miR-181 was shown to target
NLK, a negative regulator of the Notch pathway, which is
essential for lymphocyte development. Notch signals have
been shown to support in vitro human NK cell diﬀerentiation
[67–69], and this work demonstrates a role for miR-181
family members in regulating NK cell development, possibly
through modulating NLK and Notch in lymphoid or NK cell
progenitors.
6. MicroRNA Regulation of NK Cell Function
The production of IFN-γ, a key immune cytokine produced
in abundance by activated NK cells, is complex and involves
the integration of multiple signaling pathways [8] and multi-
ple layers of regulation [70]. In terms of posttranscriptional
regulation, studies have previously indicated a role for a
5′ psuedoknot and 3′ AU-rich elements in the stability of
the IFN-γ transcript [71], and miRNA-mediated regulation
has also recently been reported. As discussed previously,
the eﬀect of Dicer1 elimination in T cells and NK cells is
to increase IFN-γ production [39, 53, 54], demonstrating
that IFN-γ is a target (whether direct or indirect) of
Dicer1-dependent miRNAs. While many miRNAs have been
proposed to alter IFN-γ production, these eﬀects may be
due to suppression of upstream signaling components. For
example, miR-181a/b was linked to indirect human NK cell
IFN-γ regulation, with overexpression using lentivirus based
approaches reported to increase IL-12-plus IL-18-induced
IFN-γ production following 14-day culture in IL-15 [66]. In
addition, STAT4, a key mediator of IL-12-induced signals,
was reported to be targeted by miR-132, 212, and 200a
[72]. Several miRNAs, including the miR 17∼92 cluster are
expressed in NK cells [37], and have been shown to regulate
IFN-γ in T cells [73]. Further study of such candidate
miRNAs in NK cells is warranted, since mRNA targets may
diﬀer between these two distinct cell lineages. Three miRNA
families have been found to speciﬁcally target IFN-γ or genes
immediately upstream of its induction: miR-29, miR-155,
and miR-15/16 (Figure 2).
MiR-29 demonstrates modest expression in resting NK
cells [37], and has been shown to regulate the IFN-γ pathway
by two independent laboratories [74, 75]. However, these
studies report somewhat diﬀering mechanisms of regulation
based on proposed miR-29 targets. Ma et al. showed a direct
regulation of IFN-γ in NK and T cells, and used an in vivo
sponge model targeting miR-29 resulting in increased IFN-γ
protein production [74]. In contrast, Steiner et al. showed, in
CD4+ T cells, an indirect regulation of T-bet and Eomes, two
important transcription factors that induce IFN-γ mRNA,
but no direct regulation of IFN-γ mRNA by miR-29 [75].
Additional in vitro studies by our lab in 293T cells utilizing
luciferase sensor-plasmids failed to identify the murine IFN-
γ 3′UTR as a direct target of miR-29 [39]. Further study will
be required to clarify the precise role of miR-29 in IFN-γ
regulation in NK cells using NK cell-speciﬁc genetic models.
MiR-155, the miRNA product of the BIC non-coding
RNA, has been previously shown to play a role in B [76–
79], T cell [80, 81], dendritic cell [82], and macrophage
[83] biology. While miR-155 is modestly expressed in resting
mouse and human NK cells, it has markedly increased
expression following combined cytokine activation with IL-
12 plus IL-18, peaking at 24 hours ([37, 84] and Leong,
Sullivan, and Fehniger; unpublished data). MiR-155 is not
predicted to directly target the human or mouse IFN-γ
3′UTR. Trotta and colleagues have reported miR-155 as a
positive regulator of IFN-γ production from mature human
NK cells following IL-12 plus IL-18 activation, through
repression of SHIP-1 [85], an established negative regulator
of PI3 K-induced IFN-γ production [84]. Additional studies
evaluating miR-155 in the context of in vivo infection and
tumor models will help to clarify the relative importance of
miR-155 induction on NK cell responses in vivo. In addition,
it is likely that miR-155 targets additional mRNAs during
activation, that regulate the NK cell activation program.
Thus, while miR-155 has a clear role in regulating IFN-γ
production and targets SHIP-1, it likely has pleiotropic
eﬀects, controlling diﬀerent aspects of NK cell homeostasis
and eﬀector function.
The miR-15/16 family is encoded from two distinct
loci in the genome, miR-15a/16-1 and miR-15b/16-2, which
are processed to miR-15a, miR-15b, and miR-16 mature









Figure 2: Summary of known miRNA interactions regulating
IFN-γ or immediate upstream signals that induce IFN-γ in NK cells.
miRNAs. This family has been shown to regulate cell survival
(Bcl2), cell cycle (cyclin D1), and has been implicated in the
development or progression of several malignancies, includ-
ing chronic lymphocytic leukemia [86, 87]. Mir-15a, 15b,
and 16 are among the most abundantly expressed miRNAs
in NK cells, suggesting that transcription of both loci is
operative [37]. These family members are computationally
predicted to target the murine IFN-γ 3′UTR, which has been
conﬁrmed in vitro by luciferase sensor-plasmid experiments
[39]. Moreover, mature miRNAs from this family are down
regulated in primary NK cells after cytokine activation. While
these ﬁndings suggest that the miR-15/16 family of miRNAs
may be key players in regulating NK cell IFN-γ production,
additional studies utilizing in vitro and in vivo loss- and gain-
of-function will be required to deﬁne the non-redundant role
of these miRNAs on NK cell IFN-γ production.
Work on miRNAs regulating cytotoxicity has focused
on the two major granule proteins, granzyme B (GzmB)
and perforin (Prf1). Our work ﬁrst identiﬁed that both
GzmB and Prf1 transcript was readily produced in resting
murine NK cells, and was only modestly up regulated
following IL-15 activation [14]. However, protein levels and
cytotoxic capacity increased dramatically during activation,
suggesting a post-transcriptional mechanism of regulation.
As one potential candidate for GzmB regulation, miR-223
was identiﬁed as the most down-regulated miRNA following
IL-15 treatment and directly targets the murine GzmB 3′
UTR [37]. However, NK cells from miRNA-223−/− mice [88]
appear to express similar amounts of GzmB as wild type
mice at baseline, and exhibit levels of cytotoxicity similar
to wild type controls, suggesting that miR-223 alone does
not play a nonredundant role in limiting murine GzmB
translation in resting mouse NK cells (Leong and Fehniger,
unpublished data). Additional studies are still needed to
determine the ramiﬁcations of miR-223 gain- and loss-of-
function, in combination with other miRNAs, in primary
NK cells.
Two recent studies have identiﬁed miRNAs regulating
GzmB and Prf1 in human NK cells. In the ﬁrst, Kim et al.
demonstrated that miR-27a-5p (miR-27a∗) targeted both 3′
UTRs, and using in vitro diﬀerentiated NK cells (CD34+
hematopoietic progenitors cultured for several weeks in
NK cell diﬀerentiating conditions), observed reduced GzmB
and Prf1 protein with miR-27a-5p overexpression in this
system [89]. Activation with IL-15 paradoxically leads to
up regulation of this miRNA, possibly serving to dampen
further GzmB and Prf1 production. Inhibition of miR-27a-
5p in these diﬀerentiated NK cells resulted in enhanced in
vitro killing and tumor protection in a xenograft model.
However, the miRNA and mRNA expression of in vitro
diﬀerentiated NK cells that require long-term culture to
freshly isolated primary human NK cells are an important
caveat to these ﬁndings. Indeed, miR-27a-5p (miR-27a∗)
is expressed at very low levels in both mouse [37] and
human resting NK cells [36], suggesting a limited role for
this miRNA outside of extensive cytokine activation or ex
vivo culture. Additional loss-of-function data in primary
human NK cells would help support the role of miR-27a-5p
in regulating GzmB and Prf1.
In contrast to the rheostat model of miR-27a-5p, mature
miR-378 and miR-30e expression is reduced upon IFN-α
stimulation, releasing repression of GzmB and Prf1 [35].
Expression of both miRNAs was shown to be inversely
correlated with GzmB and Prf1 protein production. Further,
nucleofection of miRNA sponges against either miRNA-378
or miR-30e in NK-92 cells leads to enhanced cytotoxicity
against K562 tumor targets. In another study using the
human NKL cell line, stimulation through NKG2D led to
downregulation of a number of miRNAs [90]. One of these
miRNAs, miR-30c-1-3p (miR-30c-1∗) was shown to target
HMBOX1, an inhibitory transcription factor of cytokine
secretion. Overexpression or inhibition of miR-30c-1-3p
resulted in altered killing against two hepatoma cell lines,
again with caveat that additional validation using primary
NK cells is needed. Collectively, these studies provide evi-
dence that cytotoxic eﬀector molecules, including GzmB and
Prf1, are controlled by miRNAs in NK cells. Since diﬀerences
in 3′UTRs exist between human and mouse granzyme B and
perforin, careful evaluation of each candidate miRNA in both
species will be required to fully understand their roles in
regulating NK cell cytotoxicity.
7. Target Cell MicroRNAs: Regulation of
NK Cell Recognition
NK cell recognition of virus-infected and tumor targets
depend on a complex interplay between signals from activat-
ing and inhibitory NK cell receptors [2, 10]. NKG2D is one
of the best characterized activating NK cell receptors with
ligands that are up regulated in the setting of viral infection
or genotoxic stress [91, 92]. The Mandelboim lab was the
ﬁrst to demonstrate that one human NKG2D ligand, MICB,
was directly targeted by a miRNA encoded by the human
CMV virus, hcv-miR-UL112-1. This resulted in decreased
binding of NKG2D on NK cells to virus-infected cells, as
well as reduced NK cell mediated cytotoxicity, suggesting that
the viral miRNA was an immune evasion utilizing the target
cell’s RISC apparatus [93]. Similar virally-encoded miRNAs
that target and thereby down-regulate MICB expression
were described in other herpesviruses, including Kaposi’s
sarcoma-associated herpesvirus (KHSV) and Epstein-Barr
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virus (EBV) [94]. These studies also led to examination of
endogenous cellular miRNAs as regulators of NKG2D ligand
expression (i.e., miRs-20a, 93, 106b, 372, 373, and 520d),
which were shown to directly target MICA and MICB. In
vitro overexpression of a pool of these miRNAs resulted
in decreased MICA/MICB expression, and in turn blunted
NKG2D-based NK cell recognition, suggesting miRNAs as
a “tuning” mechanism for NKG2D ligand expression, that
may be relevant for cancer cell immunoevasion [95]. Thus,
both cellular and virally-encoded miRNAs inﬂuence NK cell
responses in a cell extrinsic fashion via altering activating
NK cell receptor ligand expression. While not yet reported,
it seems reasonable to speculate that this mode of NK cell
receptor ligand regulation by target cells may extend to other




NK cell malignancies arise in diﬀerent forms, varying from
a chronic NK cell lymphocytosis, more aggressive nasal-
type NK/T cell lymphomas, to rapidly progressing, highly
aggressive NK cell leukemia/lymphoma [96–98]. Patients
with NK cell cancers are rare, and to date only limited
mouse models mimicking the disease have been available [99,
100], hampering mechanistic studies of the molecular events
important for transformation and progression. Alterations
in miRNA expression through varying mechanisms, as well
as somatic mutation, have been reported in patients with
hematologic malignancies, as well as animal models of
other lymphoid cancers [48, 87]. Several reports have now
examined the expression of miRNAs in NK cell cancers,
primarily nasal-type T/NK lymphomas. Yamanaka and col-
leagues [31] reported aberrant overexpression of miR-21
and/or miR-155 in malignant NK cell lines (N = 10) and
primary patient samples (N = 10). Further, utilizing loss of
function approaches in immortalized NK cell lines derived
from patients with NK malignancies, the authors linked
pathologic overexpression of miR-21 with targeting and
decreased expression of two tumor suppressors: phosphatase
and tensin homolog (PTEN) and programmed cell death
4 (PDCD4). In addition, overexpression of miR-155 was
linked with targeting of Src homology-2 domain-containing
inositol 5-phophatase 1 (SHIP-1), a negative regulator of the
PI3 K-AKT signaling pathway [101]. This study suggests that
several miRNAs converge and cooperate in altering common
signal pathways in NK cell malignancy, resulting in this
case in enhanced AKT signaling and consequent enhanced
cell survival, proliferation, and NF-κB activation (Figure 3).
Additional studies will be required to determine the fre-
quency and extent of miR-21 and miR-155 overexpression in
NK cell cancers, and their correlation with clinical outcomes.
Ng et al. [102] evaluated the prognostic impact of candidate
miRNA in a set of 50 extra nodal NK/T cell lymphomas
and identiﬁed that low relative expression of miR-146a
was an independent poor prognostic factor. Further, forced
overexpression of miR-146a in NK cell lines inhibited NF-
κB signals, suppressed proliferation, induced apoptosis, and
enhanced the chemosensitivity of these NK/T cell lines
(SNK6, YT). The authors hypothesize that this occurs via
miR-146a suppression of TRAF6, which was also down-
regulated upon forced miR-146a overexpression, and induces
downstream NF-κB signals. For patients with low miR-146a,
this would result the loss of a normally present negative feed-
back loop mediated by miR-146a (Figure 3). A third study
by Ng and colleagues evaluated nasal-type NK/T lymphomas
(n = 30) for alteration in candidate miRNA expression
using miRNA microarrays, and concluded that miRNAs are
predominantly down-regulated, including miR-101, 26a/b,
28-5p, 363, and 146a, compared to non-malignant peripheral
blood NK cells [102]. This study identiﬁed an 11-fold (NK
cell lines) and 2-fold (primary NK tumors) increase in miR-
155, compared to normal donor CD56+CD3− NK cells,
and no alteration in miR-21 was reported. This suggests
that miR-155 and miR-21 overexpression may be variably
dysregulated in patients with these malignancies, or that
diﬀering technical approaches may bias miRNA proﬁling
study ﬁndings, highlighting again the need for consistent
normalization approaches and validation of results using
secondary, orthogonal miRNA detection techniques. The
authors identify correlations between deregulated miRNAs
and overexpression of IRF4, BLIMP1, and STMN1 in pri-
mary samples, although these have not yet been conﬁrmed
using gain or loss of function studies. For each of these
candidate miRNAs, it will be important in future studies to
support the potential for oncogenic activity by investigating
model organisms using genetic gain or loss of candidate
miRNA function, restricted to the NK cell compartment.
Further, if these miRNA alterations appear to causally
contribute to pathogenesis or progression, they may be
potentially targeted using miRNA antagomiRs or mimics in
vivo.
There is a strong association between infection with
Epstein-Barr virus (EBV) and a subset of NK/T cell
leukemia/lymphomas, with many associated with direct EBV
infection and a type 2 latency program. Ramakrishnan et
al. proﬁled such NK cell lymphoma cell lines, and identiﬁed
EBV encoded miRNAs that were abundantly expressed [103].
In vitro loss of function of several EBV-miRs (BART7, 9,
17-5p) resulted in reduced cell division rates in some, but
not all, immortalized NK cell lines without aﬀecting cell
viability. In vitro studies also showed that EBV-miR-BART9
had a positive correlation with the latency protein LMP-1
in these cell lines, using overexpression and knock-down in
vitro. These results, while intriguing, require conﬁrmation in
additional NK cell lines, and primary malignancy samples. In
addition, further studies will be required to fully evaluate the
functional impact and importance of EBV-encoded miRNAs
in NK tumor cells infected with EBV.
9. Conclusions
MiRNAs represent a relatively recently discovered, but highly
important, post-transcriptional mode of gene regulation
in NK cells. Studies have started to deﬁne the expression
of mature miRNAs in human and mouse NK cells, iden-
tiﬁed the importance of miRNAs in NK cell biology in

































Figure 3: Summary of miRNA alterations identiﬁed in NK/T malignancies and proposed mechanisms of altering cell growth and survival.
(a) Increased miR-21 and miR-155 was identiﬁed in malignant cases by Yamanaka et al. [31]. (b) Decreased miR-146a were identiﬁed in
malignant cases by Paik et al.
models of global gain or loss of miRNAs, and advanced
our understanding of the complex mechanisms whereby
individual miRNAs target speciﬁc mRNAs to inﬂuence the
NK cell molecular program. With over 60 highly expressed
miRNAs detected in NK cells, it is now critical to investigate
their targets and functional impact in all areas of NK cell
development and function.
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